三探头脱氧葡萄糖符合线路断层显像在诊断肺癌中的应用  

The role of [^(18)F] fluorodeoxyglucose triple-head coincidence imaging in the diagnosis of suspected lung cancer

作　　者：魏博[1] 王天佑[1] 龚民[1] 吕可洁[1] 李春林[2] 邹兰芳[2] 

机构地区：[1]首都医科大学附属北京友谊医院胸心血管外科 [2]首都医科大学附属北京友谊医院核医学科,100050

出　　处：《中华外科杂志》2005年第2期80-82,共3页Chinese Journal of Surgery

摘　　要：目的评价三探头脱氧葡萄糖符合线路断层显像(FDGTHTC)诊断肺癌的准确性。方法对比观察109例肺部疾病患者行FDGTHTC检查的结果及其最终病理诊断,按病灶直径(>15cm、≤15cm)分别计算FDGTHTC诊断不同体积病灶的敏感性、特异性、准确性。结果病理检查显示,109例患者中86例为肺癌,23例为良性疾病。全组FDGTHTC的诊断敏感性、特异性、准确性分别为95%(82/86),74%(17/23),91%(99/109)。FDGTHTC诊断的敏感性、特异性、准确性,病灶直径≤15cm者分别为1/3,7/7,8/10,直径>15cm者分别为98%(81/83),63%(10/16),92%(91/99),其中FDGTHTC诊断前者的敏感性明显低于后者,两组间差异有统计学意义(Fisher精确概率法检验,P=0005)。结论FDGTHTC是诊断肺癌较为有用的检查手段,对直径≤15cm的病灶诊断价值较低。Objective To evaluate the accuracy of [18F]fluorodeoxyglucose (FDG) triple-head coincidence imaging in the setting of suspected lung cancer. Methods 109 patients with suspected lung cancer were enrolled in the present study. According to the diameter of the lesion(>1.5 cm、≤1.5 cm), patients were divided into two groups. The sensitivity, specificity and accuracy of the results were calculated and the results were compared with pathological results.Results Of the total of 109 patients, 86 cases were confirmed as lung cancer whereas 23 cases were benign by pathological study. The sensitivity, specificity and accuracy of FDG imaging were 95%(82/86), 74%(17/23) and 91% (99/109), respectively. For the group of lesion diameter >1.5 cm, the sensitivity, specificity and accuracy were 98%(81/83)), 63%(10/16) and 92%(91/99), respectively. While for the group of lesion diameter≤1.5 cm, the results were 1/3,7/7,and 8/10, respectively.The difference between the two groups was significant (P=0.005). Conclusions The technique of [18F]FDG imaging is an useful method for routine evaluation of patients with suspected lung cancer. The sensitivity of detection is related to lesion size, if lesions≤1.5 cm in diameter the results of FDG imaging should be carefully analyzed.

关 键 词：诊断 FDG 肺癌 病灶 断层显像 脱氧葡萄糖 符合线路 特异性 体积 肺部疾病 

分 类 号：R734.2[医药卫生—肿瘤] R817[医药卫生—临床医学]